Bright future ahead for ICN Polfa Rzeszów

"Valeant is restructuring and withdrawing from analytical, biomedical and other activities not directly connected with the production of pharmaceuticals. It will also concentrate on the most prospective markets, and Poland is among the top eight European markets," said Mariusz Gajowniczek, president of ICN Polfa. The Polish plant will most likely take over production of Valeant's Hungarian factory and part of its Spanish operations. In 2004, ICN Polfa plans to increase sales by at least 15% and will continue to invest in licenses, technologies and new drugs. (Puls Biznesu, pp. 1, 8) M.M.